



1614

PATENT RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Alan Collis, et al.

Application No.: 09/871,564

Filed: May 31, 2001

Title: Heteroaryl-cyclic Acetals

Examiner: To be determined
Art Unit: 1614

TECH CENTER 1600/2800
MAR 10 2003

I hereby certify that this correspondence, along with any referred to herein as enclosed or submitted herewith, is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

March 3, 2003

Date of Deposit
Cheryl A. Molle
Cheryl A. Molle

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. 1.56, 1.97 AND 1.98**

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith a list on the enclosed form 1449, and copies of patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement, pursuant to 37 C.F.R. 1.97(h), is not intended to constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention.


Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

Listed reference EP 0146862, a copy of which is enclosed, is in the German language, and no translation is currently available. However, listed reference U.S. Patent No. 4,659,503

is in the same patent family, and is believed to generally cover similar subject matter. These references disclose series of pyridylthiophenes having liquid crystal properties.

This Information Disclosure Statement is being filed within the period set forth in §1.97(b) because it is believed to be filed before the mailing date of a first Office Action on the merits. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) to Deposit Account No. 18-1982, upon which the undersigned is authorized to draw.

Respectfully submitted,



Paul R. Darkes, Registration No. 33,862
Attorney for Applicants

March 3, 2003
Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3638
Telefax (908) 231-2626
Aventis Docket No. CA 2295 US CNT

